After three decades climbing the ranks at medical device giants like Boston Scientific and Baxter, a seasoned executive faced a choice that would have given most leaders pause: take the safe route to a public company CEO role, or dive headfirst into the uncertain world of AI in healthcare. The pull toward AI proved irresistible.
AI That Fits the Clinical Workflow: Interview with Anumana CEO Maulik Nanavaty
Related Articles
Trial demonstrates early AI-guided detection of heart disease in routine practice
Medical Xpress: Heart disease can take a number of forms, but some types of heart disease, such as asymptomatic low ejection fraction, can be hard to recognize, especially in the…{post_date: F d, Y}
New Ventures To Use AI To Target Heart Disease
Innovator News: Mayo Clinic announced a new technology platform and launched two new companies April 14 that promise to improve doctors’ ability to spot disease early by connecting data from…{post_date: F d, Y}
New Study Demonstrates Value of AI-Enabled EKG Algorithm in Routine Practice
AZO Robotics: The EAGLE—short for ECG AI-Guided Screening for Low Ejection Fraction—trial attempted to establish whether an artificial intelligence (AI) screening tool designed to spot low ejection fraction through EKG…{post_date: F d, Y}
Anumana’s AI algorithm for cardiac amyloidosis gets FDA breakthrough nod
Bioworld: Anumana Inc. has garnered a U.S. FDA breakthrough device designation for its artificial intelligence (AI)-powered electrocardiogram-based algorithm for early identification of cardiac amyloidosis. The ECG-AI detection algorithm is the…{post_date: F d, Y}